Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development, manufacture and ...

Alumis (NASDAQ:ALMS) stock surges 14% after the company reached a licensing deal with Kaken (KKPCF) for its skin disorder ...

Charles Schwab Investment Management Inc. increased its holdings in shares of Alumis Inc. (NASDAQ:ALMS – Free Report) by 4.4% ...

Stock analysts at HC Wainwright upped their Q1 2025 EPS estimates for Alumis in a report released on Wednesday, March 26th.

We recently published a list of Thursday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...

Alumis stock is trading higher on Tuesday after the company announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals.

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...

Last week’s deal-making news included US biotech Alumis signing a licensing agreement with Japan’s Kaken Pharma for its ...

Alumis shares rose after the company signed a licensing agreement, worth $40 million in the short-term, with Tokyo-based Kaken Pharmaceutical. The stock climbed 17.9% to $4.45 on Tuesday, recovering ...

Alumis (ALMS) and Kaken Pharmaceutical announced that the companies have entered into a collaboration and licensing agreement to develop, ...